Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Response to antiretroviral therapy in HIV-infected ugandan children exposed and not exposed to single-dose nevirapine at birth
Journal of Acquired Immune Deficiency Syndromes, Volume 52, No. 5, Year 2009
Notification
URL copied to clipboard!
Description
OBJECTIVE: To compare the response to a nevirapine (NVP)-based highly active antiretroviral therapy (HAART) in HIV-infected Ugandan children, exposed and nonexposed to single-dose NVP (sd NVP) at birth. METHODS: HIV-infected study children were initiated on stavudine/lamivudine/NVP as a fixed dose combination. CD4 cell percent and HIV-1 RNA were documented at baseline, 12, 24, 36, and 48 weeks post-initiation of HAART. RESULTS: Ninety-two children were enrolled in the study, 44 in the sd NVP-exposed and 48 in the nonexposed cohort. The median age at enrollment was 1.7 years [interquartile range (IQR) 1.2-2.4] and 7.8 years (IQR 5.9-9.2) in the sd NVP-exposed and nonexposed cohorts, respectively (P < 0.001). At baseline and week 48 post-HAART, the median CD4 cell percentages were 14% and 33% for the NVP-exposed group and 8% and 22.5% in the nonexposed group (P < 0.0001). The median (IQR) viral load at baseline was 650,568 (359,979-2,086,613) RNA copies/mL and 239,027 (105,904-494,813) RNA copies/mL in the NVP-exposed and nonexposed cohorts, respectively. After 48 weeks of HAART, 76% of the NVP-exposed and 80% of the nonexposed children had a median viral load of <400 copies/mL (P = 0.74). CONCLUSIONS: Both HIV-infected Ugandan older infants and children that were exposed and not exposed to sd NVP at birth had favorable treatment outcomes on NVP-containing HAART. © 2009 by Lippincott Williams & Wilkins.
Authors & Co-Authors
Musoke, Philippa Martha
United States, Baltimore
Johns Hopkins University
Uganda, Kampala
Makerere University
Barlow-Mosha, Linda Namutebi
United States, Baltimore
Johns Hopkins University
Bagenda, Danstan S.
United States, Baltimore
Johns Hopkins University
Uganda, Kampala
College of Health Sciences
Mudiope, Peter K.
United States, Baltimore
Johns Hopkins University
Mubiru, Michael Charles
United States, Baltimore
Johns Hopkins University
Ajuna, Patrick
United States, Baltimore
Johns Hopkins University
Tumwine, James Kashugyera
Uganda, Kampala
Makerere University
Fowler, Mary Glenn
United States, Baltimore
Johns Hopkins University
Statistics
Citations: 28
Authors: 8
Affiliations: 3
Identifiers
Doi:
10.1097/QAI.0b013e3181b93a5a
ISSN:
15254135
Research Areas
Infectious Diseases
Maternal And Child Health
Study Design
Cohort Study